Global Hormone Refractory Prostate Cancer (HRPCA) Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|激素抗性前列腺癌症(HRPCA)的全球市場(2020年∼2027年) Global Hormone Refractory Prostate Cancer (HRPCA) Market - 2020-2027|
|出版日期: 2021年05月12日||內容資訊: 英文 180 Pages||
全球激素抗性前列腺癌症(HRPCA)市場主要成長要素包括前列腺癌患病率的增加、強大的管道藥物的出現、患者意識的提高以及前列腺癌新療法的出現。儘管 COVID-19 大流行正在影響正在進行的臨床試驗，但預計情況會隨著時間的推移而改善。然而，高昂的處理成本會阻礙市場的增長。
The Global Hormone Refractory Prostate Cancer (HRPCA) Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Hormone refractory prostate cancer is also called as Castrate-Resistant Prostate Cancer (CRPC)occurs when hormone therapy fails to stop the growth of prostate cancer for any longer. Hormone refractory prostate cancer may occur a few months or even years after hormone therapy has been started. Most prostate cancers are found during screening with a digital rectal exam or prostate-specific antigen blood test. Initially, prostate cancers usually don't show any symptoms, but sometimes symptoms can be seen in advancing cancer stages. If Hormone Refractory Prostate Cancer is suspected based on the outcomes of screening tests or symptoms, tests are needed to confirm the diagnosis. A definite diagnosis of prostate cancer can be made with a prostate biopsy. When hormones fail to stop cancer's growth and spread any longer, the next step is usually chemotherapy drugs. As patients advance into stage T3 and stage T4 of prostate cancer, they have a local extension through the lymph nodes and seminal vesicles. It has chances that cancer could metastasize to the bones. The more quickly prostate cancer grows, the more likely the diseases will respond to chemotherapy treatment.
The global Hormone Refractory Prostate Cancer (HRPCA) market growth is driven by the growing prevalance of Prostate cancers, and Emerging strong pipeline drugs, Growing patients awareness, Availability of new prostate cancer treatments are among the key factors driving market growth.
Emerging strong pipeline of drugs are increasing the demand for the global Hormone Refractory Prostate Cancer (HRPCA) market during the forecast period.
Janssen Pharmaceuticals developing niraparib for treating castration-resistant prostate cancer in combination with abiraterone acetate and Prednisone is under Phase III trials in U.S and E.U.
Bayer undergoing a Phase I trial to study is the safety and toxicity of Fractionated Docetaxel and Radium 223 in Castration-Resistant Prostate Cancer (CRPC) patients.
Increasing Prevalence of Prostate Cancers, is expected to drive the global Hormone Refractory Prostate Cancer (HRPCA) market during the forecast period.
According to the National Cancer Institute NIH, Prostate cancer is the fifth leading cause of cancer death in the United States. The rate of new prostate cancer cases was 109.8 per 100,000 men per year. In 2017, an estimated 3,170,339 men were living with prostate cancer in the United States. In 2020, it was estimated that there would be 191,930 new cases of prostate cancer. According to WHO, Prostate cancer cases estimated in 2020 were 1.41 million. These factors are driving the growth of the market in the forecast period.
High treatment costs are likely to hinder the global Hormone Refractory Prostate Cancer (HRPCA) market growth.
According to the American Cancer Society, on average, prostate cancer costs about $4,300 initially and about $9,100 over five years, and it costs about $15,000 initially and $19,000 over five years for surgery. Hormone therapy with radiation costs about $17,500 initially and $25,000 total over five years. For patients with advanced prostate cancer, costs can reach $100,000 or more.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Based on Treatment Type, the global Hormone Refractory Prostate Cancer (HRPCA) market is segmented into Chemotherapy (Cytotoxic agents), Hormone therapy (Anti-androgen agents), Radiation therapy, Surgery and Others
Prostate cancer chemotherapy treatment is almost always a salvage therapy for advanced prostate cancers. When treatments like cryotherapy or prostate surgery fail, and the next step is either another type of treatment or prostate cancer hormone therapy. Once the patient starts hormone therapy, the disease can be effectively controlled and even stops for a while. Hormone therapy will eventually fail, however, and prostate cancer will continue to grow and spread. This is called hormone-refractory prostate cancer and is commonly seen during the advanced stages of prostate cancer. Then the next step is usually chemotherapy.
Chemotherapy (Cytotoxic agents) segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Chemotherapy (chemo) uses anti-cancer drugs injected into a vein or given by mouth. These drugs travel through the bloodstream to reach cancer cells in most parts of the body. These drugs have been in the market for some time, and the growth of this segment is imminent because of the availability and cost-effective nature of these drugs. Some of the chemo drugs used to treat HRPCA include Docetaxel (Taxotere), Cabazitaxel (Jevtana), Mitoxantrone (Novantrone), Estramustine (Emcyt), Vinblastine, Carboplatin, Etoposide, Paclitaxel.
For instance, in Nov 2020, Astellas Pharma Inc. got approval under the licensor with Pfizer of MDV3100 (now Xtandi) to treat HRPCA. For instance, in Nov 2020, Astellas Pharma Inc. got approval under the licensor with Pfizer of MDV3100 (now Xtandi) to treat HRPCA.
Based on End-User, the global Hormone Refractory Prostate Cancer (HRPCA) market is segmented into Hospitals, Cancer Research centers, clinics, others.
Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.
North America served the largest share of the market due to the increasing prevalence of Metastatic prostate cancer cases. According to the American Cancer Society, the prostate cancer prevalence in 2019 estimated was 174,650 prostate cancers and in the United States for 2021 new cases are about 248,530. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced diagnostic tools, and many companies are developing oncology products.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Suzhou Kintor Pharmaceutical Inc on-going An Extended/Phase 2, Study to Evaluate the Safety and Tolerability of GT0918 in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide.
The global Hormone Refractory Prostate Cancer (HRPCA) market is quite competitive with some key competitors like AbbVie Inc, Acceleron Pharma, Inc, AB Science SA, AstraZeneca Plc, Astellas Pharma Inc, Sanofi S.A, Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Johnson and Johnson and others. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, According to clinicaltrials.gov; Merck Sharp & Dohme Corp-A Phase 2 Study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer.
Johnson & Johnson Services Inc
Company Overview: Johnson & Johnson Services Inc is an American multinational company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets and the Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular and eye health fields. Robert Wood Johnson founded the company I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ. On October 24, 1961, the company Janssen was acquired by Johnson & Johnson. In 2011, Johnson & Johnson subsidiary Centocor became Janssen Biotech, part of Janssen Pharmaceuticals. Also, in 2011, Johnson & Johnson acquired Crucell, and assigned it to Janssen. The acquisition of Crucell provided Janssen with a disease prevention arm. By 2014, Crucell was renamed Janssen Vaccines.
Product Portfolio: The Company's portfolio comprised of include immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases in Pharmaceutical segment.
Janssen Research & Development, LLCA multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Subjects with Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC).
The global Hormone Refractory Prostate Cancer (HRPCA) Market report would provide an access to an approx. 53 market data table, 45 figures and 240 pages.
LIST NOT EXHAUSTIVE